These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22189199)

  • 1. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.
    Nguyen HH; Nguyen CTT; Mai TNP; Huong PT
    Pharmacogenet Genomics; 2023 Jun; 33(4):65-78. PubMed ID: 37098851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
    Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
    Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
    Khine H; Yuet WC; Adams-Huet B; Ahmad Z
    Am Heart J; 2016 Sep; 179():1-9. PubMed ID: 27595674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.
    Martin NG; Li KW; Murray H; Putt W; Packard CJ; Humphries SE
    Br J Clin Pharmacol; 2012 Feb; 73(2):303-6. PubMed ID: 21851379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
    Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.
    Li JH; Suchindran S; Shah SH; Kraus WE; Ginsburg GS; Voora D
    Pharmacogenomics; 2015; 16(5):449-58. PubMed ID: 25916517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.
    Zhang W; Chen BL; Ozdemir V; He YJ; Zhou G; Peng DD; Deng S; Xie QY; Xie W; Xu LY; Wang LC; Fan L; Wang A; Zhou HH
    Br J Clin Pharmacol; 2007 Sep; 64(3):346-52. PubMed ID: 17439540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
    Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
    Akao H; Polisecki E; Schaefer EJ; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Packard C; Buckley BM; Kajinami K;
    Atherosclerosis; 2014 Jul; 235(1):176-81. PubMed ID: 24854628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
    Couvert P; Giral P; Dejager S; Gu J; Huby T; Chapman MJ; Bruckert E; Carrié A
    Pharmacogenomics; 2008 Sep; 9(9):1217-27. PubMed ID: 18781850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
    Hu M; Tomlinson B
    Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.
    Takane H; Miyata M; Burioka N; Shigemasa C; Shimizu E; Otsubo K; Ieiri I
    J Hum Genet; 2006; 51(9):822-826. PubMed ID: 16917677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population.
    Wu H; Huang Q; Yu Z; Wu H; Zhong Z
    Lipids Health Dis; 2020 Sep; 19(1):202. PubMed ID: 32891149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.